Accredited Investors Inc. Grows Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

Accredited Investors Inc. boosted its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) by 14.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,000 shares of the company’s stock after purchasing an additional 2,500 shares during the period. Accredited Investors Inc.’s holdings in Verve Therapeutics were worth $97,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in VERV. Nisa Investment Advisors LLC grew its stake in shares of Verve Therapeutics by 908.4% during the second quarter. Nisa Investment Advisors LLC now owns 7,714 shares of the company’s stock valued at $38,000 after buying an additional 6,949 shares during the last quarter. Creative Planning bought a new position in Verve Therapeutics in the 3rd quarter valued at $50,000. PFG Investments LLC purchased a new stake in Verve Therapeutics in the third quarter worth $53,000. Daiwa Securities Group Inc. boosted its stake in shares of Verve Therapeutics by 89.8% during the second quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock valued at $59,000 after purchasing an additional 5,723 shares during the period. Finally, Cornercap Investment Counsel Inc. boosted its stake in shares of Verve Therapeutics by 13.5% during the second quarter. Cornercap Investment Counsel Inc. now owns 14,956 shares of the company’s stock valued at $73,000 after purchasing an additional 1,778 shares during the period. Institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Price Performance

Shares of Verve Therapeutics stock opened at $4.79 on Monday. Verve Therapeutics, Inc. has a 1 year low of $4.30 and a 1 year high of $19.34. The stock has a market cap of $405.52 million, a price-to-earnings ratio of -1.95 and a beta of 1.75. The firm’s 50-day moving average is $5.45 and its two-hundred day moving average is $5.67.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.11. The company had revenue of $6.87 million for the quarter, compared to analyst estimates of $2.75 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. Verve Therapeutics’s revenue was up 120.2% compared to the same quarter last year. During the same period last year, the company posted ($0.72) earnings per share. On average, equities analysts expect that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on VERV shares. Royal Bank of Canada decreased their price objective on shares of Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Canaccord Genuity Group lifted their price target on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 6th. Finally, HC Wainwright dropped their price objective on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.